Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?

about

Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?

Item

http://www.wikidata.org/entity/Q36288817

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Early evaluation of sunitinib ...... : RECIST 1.1 or Choi Criteria?

@ast

Early evaluation of sunitinib ...... : RECIST 1.1 or Choi Criteria?

@en

type

Item

label

Early evaluation of sunitinib ...... : RECIST 1.1 or Choi Criteria?

@ast

Early evaluation of sunitinib ...... : RECIST 1.1 or Choi Criteria?

@en

prefLabel

Early evaluation of sunitinib ...... : RECIST 1.1 or Choi Criteria?

@ast

Early evaluation of sunitinib ...... : RECIST 1.1 or Choi Criteria?

@en

P1476

Early evaluation of sunitinib ...... : RECIST 1.1 or Choi Criteria?

@en

P2093

Jie Chen

http://www.w3.org/2001/XMLSchema#string

Kun Huang

http://www.w3.org/2001/XMLSchema#string

Ling Xu

http://www.w3.org/2001/XMLSchema#string

Minhu Chen

http://www.w3.org/2001/XMLSchema#string

Shi-Ting Feng

http://www.w3.org/2001/XMLSchema#string

Yanji Luo

http://www.w3.org/2001/XMLSchema#string

Yuan Lin

http://www.w3.org/2001/XMLSchema#string

Zi-Ping Li

http://www.w3.org/2001/XMLSchema#string

P2860

Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Gastroenteropancreatic neuroendocrine tumours

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver.

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

A 5-decade analysis of 13,715 carcinoid tumors.

Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.

P2888

s12885-017-3150-7

P304

154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-017-3150-7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1083861476

http://www.w3.org/2001/XMLSchema#string

P698

28231773

http://www.w3.org/2001/XMLSchema#string

P932

5324282

http://www.w3.org/2001/XMLSchema#string